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ORIGINAL RESEARCH
Objectives: Nonsteroidal antiinflammatory drugs (NSAIDS) have been shown to retard
aneurysm growth in animal models. In vitro studies have shown an inhibitory effect of NSAIDS
on matrix metalloproteinase-9, interleukin-1β, and IL-6 mediated arterial wall elastolysis.
The aim of this study was to investigate the effects of NSAIDs on arterial stiffness, a surrogate
marker of elastolysis.
Methods: 447 subjects enrolled in a community-based abdominal aortic aneurysm (AAA)
screening program were assessed for age, blood pressure, smoking status, and drug history.
Aortic diameter and stiffness were measured by M-Mode ultrasound. The concentration of
the amino-terminal propeptide of type III procollagen was used as a proxy measurement of
type III collagen turnover.
Results: NSAID ingestion was significantly (p = 0.006) associated with increased aortic wall
stiffness after adjusting for age, aortic diameter, blood pressure, and smoking status. No such
effect was seen for β-blockers, calcium channel antagonists, nitrates, angiotensin-converting
enzyme inhibitors, diuretics, or antiplatelet agents.
Discussion: These novel data show that NSAIDS are associated with increased aortic stiffness,
possibly through the effects of cytokine mediated elastolysis. This in turn may prevent aortic
expansion and the development of AAA.
Keywords: nonsteroidal antiinflammatory drugs, abdominal aortic aneurysm, aortic stiffness,
elastolysis
Introduction
The pathogenesis of abdominal aortic aneurysm formation is not fully understood.
Inflammatory processes are clearly implicated, with the principal cellular abnormality
within the wall of an aneurysm appearing to be increased proteolytic capacity resulting
in loss of elastin.
This disruption of extra cellular matrix is accompanied by an inflammatory
infiltrate and associated with increased expression of matrix metalloproteases (MMPs)
(Thompson and Parks 1996). Nonsteroidal antiinflammatory drugs (NSAIDs) have
been shown to inhibit aneurysm expansion via the inhibition of cyclooxygenase 2
pathway in an animal model. This pathway controls synthesis of prostaglandin E2
(PGE2) and thus expression of MMP-9 (Miralles et al 1999). NSAIDs have also
been shown to decrease production of PGE2, interleukin (IL)-1β, and IL-6 in an in
vitro study of the effect of indomethacin on human abdominal aortic aneurysm (AAA)
tissue (Franklin et al 1999).
Type III collagen is the major type of collagen found in large arteries, muscle,
and skin (Prockop et al 1979a, 1979b). In vitro studies have demonstrated that
aneurysmal aortic tissue is less compliant than normal aortic tissue and that this
mechanical change is related to loss of elastin from the arterial wall. This occurs as
the mechanical load shifts from elastin to collagen and the artery becomes less
compliant (Sumner et al 1970; He and Roach 1994).
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The aim of this study was to measure aortic wall
compliance, a surrogate marker of elastolysis, and compare
these values against lifestyle, proteolytic activity, and
cardiovascular status.
Methods
The subjects of this study participated in a prospective,
longitudinal, population-based screening program for men
over the age of 50 in Huntingdon, UK (Morris et al 1994).
In December 1996, 9864 men over the age of 50 had been
screened. A nested case control study was performed within
this population. A case was defined as a person with an
infrarenal aortic diameter exceeding 29 mm. A control was
defined as a person with an infrarenal aortic diameter less
than 25 mm. Controls were matched for age using frequency
matching and were selected at random from the screened
population with an aorta diameter less than 25 mm. Data
about current smoking status, smoking history, family
history of aortic aneurysm, occupational history, previous
medical history, and drug history were obtained through a
self-administered questionnaire. Smoking status was
classified into three categories: current smokers, ex-smokers,
and non-smokers. A positive history of ischemic heart
disease was recorded if the patient had suffered a myocardial
infarction, had been admitted to hospital for treatment of
angina, or had undergone a coronary bypass operation. A
positive history of diabetes was recorded if a subject was
currently using insulin or oral hypoglycemic drugs. A
comprehensive drug history was recorded, with a positive
history for exposure to a particular drug only noted if the
subject was actually taking the drug when questioned. Data
about duration of exposure to the drugs was not recorded.
All participants had their height, weight, blood pressure,
infrarenal aortic diameter, and aortic wall distensibility
measured in the same screening visit. Blood pressure was
measured automatically with a Dinamap 1846 SXP
(Critikon, Kettering, UK).
Infrarenal aortic diameter was measured by ultrasound
(Wilmink et al 1997). All measurements of the infrarenal
aortic diameter (IAD) were made by the same ultra-
sonographer. A longitudinal scan of the abdominal aorta
was made. The maximum external anteroposterior diameter
was measured at the widest part or the most distal 1 cm of
the abdominal aorta, with the patient in supine position.
Aortic distensibility was measured with M mode
ultrasound by a single ultrasonographer using a Toshiba
Capasee with a curvilinear 3.5 MHz probe (Toshiba Medical
Systems Ltd, Crawley, UK) (MacSweeney 1999). The aortic
diameter in systole and in diastole was determined by
freezing the M mode picture, at the point of diameter
measurement, if a clear trace could be obtained. The minimal
and maximal aortic diameters were determined visually.
Diameters were measured as the distance between two
cursors, which were positioned on the upper demarcation
line of the echogenic zone. In each patient, three
measurements were taken within 5 minutes of each other.
The average of three measurements was used for the strain
calculations.
Strain was defined as:
maximal systolic diameter maximal diastolic diameter
maximal diastolic diameter
− (1)
Stiffness (β) was defined as:
() ln systolic pressure diastolic pressure
strain
(2)
The elasticity of the aorta can be described as the pressure
strain elastic modulus or stiffness (β) (Wilson et al 1998).
The stiffness index is used here because it is less dependent
on pulse pressure (Länne et al 1992). Both of these variables
are inversely related to aortic distensibility.
Measurement of the ankle brachial pressure index
(ABPI) was performed in the supine position with a hand-
held Doppler (Mini Dopplex D900, Huntleigh Diagnostics,
Cardiff, UK) with an 8-MHz probe, and a standard
sphygmomanometer. The systolic brachial artery pressure
was recorded in both right and left arms. The higher of the
two pressures was used for calculation of the ABPI. The
systolic ankle pressure was recorded at the posterior tibial
artery with the cuff of the sphygmomanometer immediately
above the malleoli. The ABPI was calculated for both legs
and the lowest value was used to determine the presence of
peripheral vascular disease. Peripheral vascular disease was
deemed present if the ABPI was lower than 0.9.
Serum was taken to measure lipid levels, cotinine levels,
(Cozart Biosciences, Abingdon, UK), and collagen turnover.
Samples were taken at the time of the aortic diameter and
stiffness measurement. The samples were spun down and
the serum frozen at –20°C on the same day for analysis at a
later date. Batches of 80 serum samples were analyzed by a
single biochemist at the department of chemical pathology
at Hinchingbrooke hospital. The concentration of the amino-
terminal propeptide of type III procollagen (PIIINP) was
used as a proxy measurement of type III collagen turnover
since the aminoterminal propeptide is split off the
procollagen molecule during type III collagen synthesis
(Prockop et al 1979a, 1979b). The concentration of PIIINPVascular Health and Risk Management 2005:1(2) 151
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was measured using an equilibrium type serum radio-
immunoassay of the amino-terminal propeptide of type III
procollagen based on a highly purified specific human
antigen (Pharmacia & Upjohn Ltd, Diagnostics Division,
Milton Keynes, UK). This was done according to the
instructions of the manufacturer with the use of duplicate
200 µL aliquots of serum (Risteli et al 1988; Satta et al 1995).
The intra-assay and inter-assay coefficients of variation of
this assay are less than 5% and the sensitivity is 0.2 µg/L.
The reference range for adults based on data of Finnish
blood donors was 1.7–4.2 µg/L, with no differences between
males and females (Risteli et al 1988).
Statistical analysis
Statistical analysis was performed using analysis of variance
and linear regression methods. The association of several
factors with arterial wall stiffness was investigated by
multivariate linear regression analysis. Statistical
significance of each individual variable in the multivariate
model was tested using a t-test. All statistical analyses were
performed using STATA 5.0 for Macintosh (Stata
Corporation, College Station, Texas, USA) (Stata
Corporation 1995; Hamilton 1998).
Results
Detailed data of current medication, past medical history,
lipid levels serum cotinine levels, and serum PIIINP as a
proxy for collagen type III turnover were available for 447
subjects: 210 cases with an aorta larger than 3 cm, and 237
controls with a normal aortic diameter (Table 1). The type
of NSAID taken and the number of subjects taking each
agent is listed in Table 2. Aortic stiffness was weakly
associated with age (coefficient 0.14, p = 0.049) but was
strongly associated with aortic diameter (coefficient 4.6,
p < 0.0001). Subjects with an aortic diameter larger than 3 cm
had a significantly stiffer aorta than controls. Only 2% of
these subjects used NSAIDs compared with 8% of subjects
with an aortic diameter less than 2.5 cm (χ
2 = 8.5, p = 0.004).
The association of stiffness with age disappeared in a
multivariate model, which adjusted for both aortic diameter
and blood pressure. Since age is known to be associated
with stiffness, it was not removed from the multivariate
model. Smoking status, a history of ischemic heart disease,
diabetes, or the presence of peripheral vascular disease were
not associated with aortic wall distensibility in a multivariate
model, which was adjusted for age, aortic diameter, and
systolic and diastolic blood pressure. Similarly serum lipid,
cotinine, and PIIINP levels were not associated with aortic
wall distensibility (Table 3).
None of the major classes of cardiovascular drugs were
significantly associated with aortic wall distensibility
(Table 4). However, use of NSAIDs was significantly
associated with increased aortic wall stiffness (coefficient
6.5), and remained significantly associated with aortic wall
Table 1 Main characteristics of the study population
Variable Mean SD
N 447
Age in years 71 7.7
Height in cm 173 6.6
Weight in kg 80 12.0
Systolic BP in mmHg 156 24.0
Diastolic BP in mmHg 85 15.1
Initial AAA diameter in mm 26.5 8.1
Abbreviations: BP, blood pressure; AAA, abdominal aortic aneurysm.
Table 2 Type of nonsteroidal antiinflammatory drugs and
number of subjects taking each agent
Type of NSAID N
Ibuprofen 7
Diclofenac 6
Indomethacin 4
Ketoprofen 1
Axapropazone 1
Tiaprofenic acid 1
Sulindac 1
Piroxicam 1
Mefenamic acid 1
Total 23
Abbreviations: NSAID, nonsteriodal antiinflammatory drug.
Table 3 Relationship between aortic wall stiffness, medical
history, lipid, and cotinine and PIIINP levels in a multivariate
linear regression model adjusted for age initial aortic diameter
and systolic and diastolic blood pressure
Variable 1N/2Mean Coefficient p-value
1Current smokers 58 1.6 (1.4) 0.25
1Ex-smokers 270 –0.7 (1.2)  0.56
1History of ischemic heart disease 75 –0.2 (1.5) 0.90
1Diabetes 17 –1.6 (2.8) 0.56
1Peripheral vascular disease 95 –0.4 (1.3) 0.75
2Total cholesterol 5.85 0.35 (0.49) 0.71
2LDL cholesterol 1.15 –0.06 (0.57)  0.92
2HDL cholesterol 3.86 2.57 (1.76) 0.15
2Cotinine 82.1 0.00 (0.00) 0.81
2PIIINP 3.68 –0.20 (0.39) 0.60
NOTE: The number of subjects are classified positive for that variable. Mean
values of total cholesterol, LDL-, and HDL-cholesterol in the study population
are in mmol/L, and serum cotinine and PIIINP in µg/L.
Abbreviations: PIIINP, amino-terminal propeptide of type III procollagen; N,
number; LDL, low-density lipoprotein; HDL, high-density lipoprotein.Vascular Health and Risk Management 2005:1(2) 152
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stiffness if only controls with a normal aortic diameter were
analyzed (coefficient 4.1, SE 2.0, p = 0.03) (Table 5).
NSAID use was associated with significantly increased
PIIINP levels. Mean levels were 5.161 (95% confidence
interval [CI] 3.717–6.606) versus 3.588 (95% CI 3.476–
3.700), p-value 0.0067 (Mann-Whitney test).
Discussion
NSAID use was found to be an independent predictor of
arterial wall compliance in our model that adjusted for age,
blood pressure, and arterial diameter. No relationship was
found with cardiovascular drugs, medical history, or serum
lipid, cotinine, and PIIINP levels. Significantly increased
PIIINP levels were found in patients taking NSAID therapy.
This is likely to be a class effect as different types of NSAIDs
were taken by the participating subjects.
Neither the duration for which a patient had been taking
NSAIDs, nor the underlying diagnoses which lead to NSAID
therapy were recorded. Thus we cannot exclude the
possibility that an underlying disease state caused the change
in aortic stiffness as opposed to NSAID therapy. However,
NSAID therapy is prescribed for a wide range of disorders
and this theory is unlikely to be correct. The group studied
has a small total population, and the possibility of a sampling
error cannot be excluded.
This method of stiffness measurement is operator
dependant and difficult to verify or reproduce. Nevertheless,
the results compare favorably with a Dutch study employing
the same method to investigate carotid arteries. Their intra-
observer coefficient of measurement variation of a single
carotid artery was 30.8%. Our estimate of the coefficient of
variation is 20.2% (95% CI 19.7–20.7%) if we use the same
method of calculation of coefficient of variation; ie, calculate
the standard error of the measurements as a percentage of
the mean, instead of calculating the standard deviation of
the measurements as percentage of the mean (Kanters et al
1998).
Cyclooxygenase, in either isoform cox1 or cox2 control
synthesis of PGE2, which regulates expression of MMP-9.
PGE2 and MMP-9 are elevated in aortic aneurysms. Miralles
et al (1999) have shown that indomethacin attenuates
aneurysm growth and its effects are mediated via inhibition
of the cox2 isoform, which decreases PGE2 and MMP-9
synthesis. A large amount of research has implicated
increased MMP activity as an important factor in increased
extracellular degradation (Lassila 1993; Gronholdt et al
1998; Herman et al 2001). However, it is important to also
consider increased collagen synthesis and other extracellular
matrix proteins.
Increased PIIINP levels suggest up-regulation of type
III collagen synthesis. We found that PIINP levels are
significantly higher in NSAID users, this suggests an up-
regulation of type III collagen synthesis. This finding may
partly explain the decreased aortic compliance found in
patients taking NSAID therapy. However, the association
between stiffness, collagen turnover, and aortic aneurysms
is far less clear. It is likely that the increased stiffness is
determined to a greater extent by other extra-cellular matrix
proteins, in particular elastin. This is reflected by the lack
of an association between PIIINP and aortic stiffness in this
study population as shown in Table 3 (coefficient –0.2). We
have reported previously that no association exists between
PIIINP turnover and probability of having an aneurysm or
an expanding aneurysm (Wilmink et al 2000). The lack of
an association between aortic stiffness and PIIINP is
consistent with this previous study. The pathogenesis of
aortic aneurysms is multifactorial and poorly understood.
It has previously been suggested that decreased compliance
in aneurysmal aortas may be protective for risk of rupture.
A final increase in compliance just before rupture is thought
to reflect failure of arterial wall collagen to carry the wall
Table 4 The association between aortic wall stiffness and
cardiovascular drugs in a multivariate linear regression model
which adjusted for age, initial aortic diameter and systolic and
diastolic blood pressure
Number Number
Drug  not exposed  exposed Coefficient p-value
Beta blockers 362 85 0.7 (1.4) 0.60
Ca channel blockers 398 49 3.0 (1.75) 0.09
ACE inhibitors 410 37 –2.0 (2.0) 0.32
Nitrates 414 33 –3.6 (2.0) 0.07
Diuretics 377 70 0.9 (1.5) 0.55
Aspirin 365 82 0.8 (1.4) 0.55
NSAIDs 424 23 6.5 (2.4) 0.006
Abbreviations: ACE, angiotensin-converting enzyme; NSAIDs, nonsteriodal
antiinflammatory drugs.
Table 5 Unadjusted and adjusted mean stiffness and 95%
confidence intervals in subjects exposed to NSAID compared
to those not exposed
Adjusted
Exposure Mean  95% CI  mean 95% CI
No NSAID 19.6 18.4–20.8 19.5 18.4–20.6
NSAID 24.4 19.4–29.3 26.0 21.5–30.5
NOTE: Adjusted means were calculated using a multivariate linear regression
model adjusting for age, initial aortic diameter, and systolic and diastolic blood
pressure.
Abbreviations: CI, confidence interval; NSAID, nonsteroidal antiinflammatory
drug.Vascular Health and Risk Management 2005:1(2) 153
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load (Wilson et al 1998). Our study group consisted almost
entirely of small aneurysms. Elastin may be more important
in the initial stages of aneurysm formation. Our study
suggests that NSAID use is associated with increased aortic
wall stiffness and increased collagen turnover. However, the
aortic wall stiffness is probably to a very limited extent
determined by collagen in small aneurysms. Therefore, the
risk and benefit in terms of taking NSAIDs as protection
against aneurysm formation and rupture has not been
established by this study and cannot at this point be
recommended.
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